Bright Minds Biosciences (DRUG) Expected to Announce Earnings on Wednesday

Key Points

• Bright Minds Biosciences (NASDAQ:DRUG) is set to report its Q3 2025 earnings on August 13th, with analysts anticipating a loss of ($0.59) per share.
• The company's previous quarterly earnings beat estimates, reporting ($0.29) EPS, which was better than the expected ($0.39).
• Currently, the average price target for Bright Minds Biosciences stands at $83.25, with most analysts rating the stock as a "Moderate Buy."

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) is projected to announce its Q3 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.59) per share for the quarter.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.10. On average, analysts expect Bright Minds Biosciences to post $-1 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Bright Minds Biosciences Stock Up 11.6%

DRUG stock traded up $4.02 during midday trading on Friday, hitting $38.82. 164,381 shares of the stock traded hands, compared to its average volume of 40,092. The stock's fifty day simple moving average is $28.86 and its 200-day simple moving average is $32.12. Bright Minds Biosciences has a 1-year low of $0.94 and a 1-year high of $79.02.

Institutional Trading of Bright Minds Biosciences

A number of hedge funds have recently bought and sold shares of DRUG. Millennium Management LLC grew its holdings in shares of Bright Minds Biosciences by 376.9% in the first quarter. Millennium Management LLC now owns 192,557 shares of the company's stock valued at $6,946,000 after purchasing an additional 152,178 shares during the period. Geode Capital Management LLC purchased a new position in Bright Minds Biosciences during the second quarter worth about $1,502,000. Finally, Goldman Sachs Group Inc. purchased a new position in Bright Minds Biosciences during the first quarter worth about $802,000. Institutional investors and hedge funds own 40.52% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on DRUG. TD Cowen began coverage on shares of Bright Minds Biosciences in a research report on Tuesday, May 13th. They set a "buy" rating on the stock. Chardan Capital reissued a "buy" rating and issued a $80.00 price target on shares of Bright Minds Biosciences in a research note on Wednesday, May 21st. Cowen initiated coverage on shares of Bright Minds Biosciences in a research report on Tuesday, May 13th. They set a "buy" rating for the company. Wall Street Zen lowered shares of Bright Minds Biosciences from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Bright Minds Biosciences in a research note on Wednesday, July 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $83.25.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.